IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. (“Eagle Pharmaceuticals” or the “Company”) (Nasdaq: EGRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased shares of Eagle during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s March 18, 2016, announcement that it had received a Complete Response Letter from the FDA stating that the FDA "cannot approve the application in its present form and requested additional information" regarding the substances used in KANGIO™.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.